Lipase increased adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 7,475 adverse event reports that record the MedDRA preferred term Lipase increased. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 422 reports in the 12 months to June 2026 and 353 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,068 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 422 (under 0.1%) record this term. Reports for male patients were 44.3% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 90 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Lipase increased name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	50
Acetaminophen		50
Allopurinol	Xanthine oxidase inhibitor	41
Aspirin	Nonsteroidal anti-inflammatory drug	41
Atenolol	beta-Adrenergic blocker	52
Atezolizumab	Programmed death Receptor-1 blocking antibody	56
Atorvastatin		38
Aubagio	Pyrimidine synthesis inhibitor	26
Azathioprine	Purine antimetabolite	47
Bevacizumab	Vascular endothelial growth factor inhibitor	57
Bisoprolol	beta-Adrenergic blocker	25
Bydureon		68
Byetta	GLP-1 receptor agonist	117
Cabometyx	Kinase inhibitor	25
Cabozantinib	Kinase inhibitor	29
Capecitabine	Nucleoside metabolic inhibitor	27
Carboplatin	Platinum-based drug	82
Cisplatin	Platinum-based drug	37
Creon		33
Crestor	HMG-CoA reductase inhibitor	28
Cyclophosphamide	Alkylating drug	81
Cymbalta		29
Cytarabine	Nucleoside metabolic inhibitor	93
Dasatinib	Kinase inhibitor	45
Dexamethasone	Corticosteroid	95
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	28
Eliquis	Factor Xa inhibitor	31
Etoposide	Topoisomerase inhibitor	39
Fluorouracil	Nucleoside metabolic inhibitor	29
Gemcitabine	Nucleoside metabolic inhibitor	33
Humira		94
Hydrocortisone	Corticosteroid	34
Ibuprofen	Nonsteroidal anti-inflammatory drug	32
Iclusig	Kinase inhibitor	53
Imatinib	Kinase inhibitor	31
Imuran	Purine antimetabolite	25
Ipilimumab	CTLA-4-directed blocking antibody	173
Janumet	Biguanide	75
Januvia	Dipeptidyl peptidase 4 inhibitor	214
Jardiance	Sodium-Glucose cotransporter 2 inhibitor	41
Keytruda	Programmed death Receptor-1 blocking antibody	66
Lenvatinib	Kinase inhibitor	33
Liraglutide Flexpen		35
Lyrica		30
Mercaptopurine	Nucleoside metabolic inhibitor	34
Mesalamine	Aminosalicylate	37
Metformin	Biguanide	56
Methotrexate	Folate analog metabolic inhibitor	172
Methylprednisolone	Corticosteroid	34
Mounjaro	GLP-1 receptor agonist	202
Nexavar	Kinase inhibitor	118
Nilotinib	Kinase inhibitor	31
Nivolumab	Programmed death Receptor-1 blocking antibody	181
Omeprazole	Proton pump inhibitor	63
Oncaspar	Asparagine-specific enzyme	44
Opdivo	Programmed death Receptor-1 blocking antibody	80
Oxaliplatin	Platinum-based drug	55
Ozempic	GLP-1 receptor agonist	107
Pantoprazole	Proton pump inhibitor	50
Pegaspargase	Asparagine-specific enzyme	43
Pembrolizumab	Programmed death Receptor-1 blocking antibody	47
Ponatinib		52
Prednisolone	Corticosteroid	47
Prednisone	Corticosteroid	168
Quinine	Antimalarial	52
Ramipril	Angiotensin converting enzyme inhibitor	35
Remicade	Tumor necrosis factor blocker	33
Ribavirin	Nucleoside analog antiviral	33
Rituximab	CD20-directed cytolytic antibody	68
Rosuvastatin	HMG-CoA reductase inhibitor	29
Saxenda	GLP-1 receptor agonist	29
Scemblix		39
Simvastatin	HMG-CoA reductase inhibitor	61
Sulfadiazine		49
Sutent	Kinase inhibitor	37
Tasigna	Kinase inhibitor	217
Teduglutide	GLP-2 analog	25
Torsemide	Loop diuretic	28
Tramadol		33
Trametinib	Kinase inhibitor	39
Trulicity	GLP-1 receptor agonist	174
Victoza	GLP-1 receptor agonist	227
Vincristine		74
Vincristine sulfate	Vinca alkaloid	63
Votrient	Kinase inhibitor	27
Wegovy	GLP-1 receptor agonist	26
Xarelto	Factor Xa inhibitor	79
Yervoy	CTLA-4-directed blocking antibody	37
Zepbound	GLP-1 receptor agonist	68
Zyprexa	Atypical antipsychotic	34

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 56 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Lipase increased name, in order of name
Class	Reports with this term
Aldosterone antagonist	27
Alkylating drug	119
Aminosalicylate	53
Angiotensin 2 receptor blocker	57
Angiotensin converting enzyme inhibitor	44
Anthracycline topoisomerase inhibitor	57
Anti-epileptic agent	65
Antimalarial	54
Antimetabolite immunosuppressant	25
Aromatase inhibitor	31
Asparagine-specific enzyme	87
Atypical antipsychotic	177
Azole antifungal	25
Benzodiazepine	48
beta-Adrenergic blocker	90
Biguanide	162
Calcineurin inhibitor immunosuppressant	41
CD20-directed cytolytic antibody	88
Corticosteroid	414
CTLA-4-directed blocking antibody	222
Cytochrome P450 3A inhibitor	37
Dipeptidyl peptidase 4 inhibitor	252
Factor Xa inhibitor	115
Fluoroquinolone antibacterial	30
Folate analog metabolic inhibitor	199
GLP-1 receptor agonist	996
GLP-2 analog	48
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	80
HMG-CoA reductase inhibitor	176
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	57
Insulin analog	28
Janus kinase inhibitor	28
Kinase inhibitor	1,080
Loop diuretic	60
Microtubule inhibitor	33
Nitroimidazole antimicrobial	29
Nonsteroidal anti-inflammatory drug	102
Nucleoside analog antiviral	35
Nucleoside metabolic inhibitor	260
Opioid agonist	68
Penicillin-class antibacterial	42
Platinum-based drug	174
Programmed death Receptor-1 blocking antibody	441
Proteasome inhibitor	31
Proton pump inhibitor	163
Purine antimetabolite	83
Pyrimidine synthesis inhibitor	38
Serotonin and norepinephrine reuptake inhibitor	37
Serotonin reuptake inhibitor	77
Sodium-Glucose cotransporter 2 inhibitor	71
Tetracycline-class antibacterial	37
Topoisomerase inhibitor	45
Tumor necrosis factor blocker	85
Vascular endothelial growth factor inhibitor	72
Vinca alkaloid	73
Xanthine oxidase inhibitor	43

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Lipase increased, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Lipase increased
Age	Reports	Share
Under 2	39	0.5%
2 to 11	167	2.2%
12 to 17	161	2.2%
18 to 44	1,030	13.8%
45 to 64	2,140	28.6%
65 to 74	1,094	14.6%
75 and over	640	8.6%
Age not given	2,204	29.5%

Sex of the patient in the reports that record Lipase increased
Sex	Reports	Share
Female	3,338	44.7%
Male	3,314	44.3%
Unknown or not given	823	11%

Age and sex are as the report gives them. 43.2% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Lipase increased: adverse event reports that record this term. https://reportedreactions.com/reaction/lipase-increased/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Lipase increased mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page